Mode
Text Size
Log in / Sign up
Phase 4 N=41 Treatment

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

Seborrheic Keratosis

Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Subject Satisfaction — 21; 14; 4; 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
A-101 Topical Solution (Drug)
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
Aclaris Therapeutics, Inc.
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Subject Satisfaction
21; 14; 4; 0; 2
SECONDARY
Effectiveness of Treatment
-2.0
SECONDARY
Comparison of Physician Lesion Assessment Score (PLA) to Subject Satisfaction
.318

Summary

This study is an open-label study designed to evaluate subject's satisfaction after treatment of seborrheic keratoses with A-101 40%.

Eligibility Criteria

Inclusion Criteria

  • Subject can comprehend and is willing to sign an informed consent for participation in this study.
  • Male or female between the ages of 30 and 75 years old.
  • Subject has 3 eligible Seborrheic Keratoses; 2 target SKs must be on the face, and the additional 1 target SK must be on the neck or decolletage.
  • Subjects must have had cryosurgery for SK removal within the last 6 months and prior to first treatment with A-101 Topical Solution.
  • Target and non-target SKs must not have been previously treated.
  • Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any target or non-target SK or which exposes the subject to an unacceptable risk by study participation

Exclusion Criteria

  • Subject has clinically atypical and /or rapidly growing Seborrheic Keratoses.
  • Subject has current systemic malignancy.
  • Subject would require the use of any topical treatment (e.g., moisturizers, sunscreens) to any of the target or non-target SKs 12 hours prior to any study visit.
  • Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03487588). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search